Results 101 to 110 of about 48,653 (304)

Primary ciliary dyskinesia: mechanisms and management

, 2017
Nadirah Damseh,1 Nada Quercia,1,2 Nisreen Rumman,3 Sharon D Dell,4 Raymond H Kim5 1Division of Clinical and Metabolic Genetics, 2Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada; 3Pediatric Department, Makassed Hospital ...
Kim RH, Damseh N, Dell SD, Rumman N, Quercia N   +4 more
core  

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence

Therapeutics and Clinical Risk Management, 2018
Sagari Bette, Danielle S Shpiner, Carlos Singer, Henry Moore Department of Neurology, Division of Parkinson’s Disease and Movement Disorders, University of Miami – Miller School of Medicine, Miami, FL, USA Abstract: Safinamide (Xadago®)
Bette S, Shpiner DS, Singer C, Moore H
doaj  

Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats

Drug Design, Development and Therapy, 2016
Lu Song,1,* Zhanzhao Zhang,2,* Rongguo Hu,1 Jie Cheng,1 Lin Li,1 Qinyi Fan,1 Na Wu,1 Jing Gan,1 Mingzhu Zhou,1 Zhenguo Liu11Department of Neurology, Xinhua Hospital, 2Department of Plastic and Reconstructive Surgery, Shanghai 9th People’s Hospital,
Song L, Zhang ZZ, Hu RG, Cheng J, Li L, Fan QY, Wu N, Gan J, Zhou MZ, Liu ZG   +9 more
doaj  

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Tardive dyskinesia

, 2020
Tardive dyskinesia is now widely recognised as a neurological disorder associated with the administration of antipsychotic drugs. Prevalence is higher among the elderly.
Blowers, Anthony John
core  

Primary ciliary dyskinesia: a biopsychosocial approach [PDF]

, 2016
Background: Primary ciliary dyskinesia (PCD) is a rare heterogeneous genetic disorder associated with abnormal ciliary structure and function and characterised by progressive sinopulmonary disease. There is no ‘gold standard’ for diagnosing PCD.
Behan, Laura
core  

Amisulpride withdrawal dyskinesia: a case report

, 2017
Background The effects of antipsychotic drug withdrawal have been inadequately studied. Case reports have described dyskinesia occurring in patients with several antipsychotics withdrawn, but studies on amisulpride withdrawal dyskinesia are lacking. Case
Yu-Chi Lo, Ying-Chieh Peng
core   +1 more source

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder

Frontiers in Pharmacology, 2017
Guanosine (GUO) is a guanine-based purine nucleoside with important trophic functions and promising neuroprotective properties. Although the neuroprotective effects of GUO have been corroborated in cellular models of Parkinson’s disease (PD), its ...
Caio M. Massari, Marc López-Cano, Marc López-Cano, Fabiana Núñez, Fabiana Núñez, Víctor Fernández-Dueñas, Víctor Fernández-Dueñas, Carla I. Tasca, Carla I. Tasca, Francisco Ciruela, Francisco Ciruela   +10 more
doaj   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

New and emerging treatments for symptomatic tardive dyskinesia

, 2013
Abdul Qayyum Rana,1–4 Zishan M Chaudry,5 Pierre J Blanchet6 1Parkinson's Clinic of Eastern Toronto and Movement Disorders Centre, Toronto, ON, Canada; 2Scarborough Memory Program, Toronto, ON, Canada; 3Journal of Parkinsonism and RLS, Toronto ...
Rana AQ, Chaudry ZM, Blanchet PJ
core